Answers are grounded in this paper and cite their sources.
The coronavirus disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is an ongoing threat to public health. Due to the presence of neutralizing antibodies in convalescent patients, convalescent plasma transfusion has been tested as a promising therapy for severe COVID-19 patients. 1 , 2 We and others previously found a surprisingly early serum IgA antibody response in the COVID-19 patients. 3 , 4 However, the relative contribution of the IgA antibody towards virus neutralization with respect to other antibody isotypes is unknown.
No takes yet. Share an insight, caveat, or question.
Zeng et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: